SITCO Pharma

sitcopharma.com

Saudi International Trading Company Ltd. (SITCO Pharma), is engaged in the Pharmaceutical distribution business in Saudi Arabia. The company, formed in 1990, is considered a leader in the field of pharmaceutical distribution in the Kingdom of Saudi Arabia. Representing several major multinational pharmaceutical companies, SITCO Pharma has quickly established the standards for excellence in its field. The management of SITCO Pharma includes 8 senior managers, each with an average of over 13 years of service and experience in Saudi Arabia. The rapid growth of SITCO Pharma is a testimony to the commitment and dedication of management and staff.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ALEXION BETS $1.4B ON PORTOLA AND ITS LAGGARD BLEEDING DRUG ANDEXXA

Fiercepharma | May 05, 2020

news image

Alexion has made no secret of its plan to diversify beyond its blockbuster rare disease franchise. Now, the company has taken a flier out on a disappointing drug that targets severe bleeding—and it's hoping to parlay its hospital contacts into a sales boost that'll appease unruly investors. Alexion agreed to buy Portola Pharmaceuticals and its sole approved medicine, anticoagulant reversal agent Andexxa, in a deal valued at around $1.4 billion, the drugmakers said Monday. That'...

Read More

Business Insights

IKTOS AND THE UNIVERSITY OF DUNDEE, DRUG DISCOVERY UNIT (DDU) ANNOUNCE A COLLABORATION TO USE AI FOR DRUG DESIGN AND RETROSYNTHEIS

Iktos | December 20, 2021

news image

Iktos, a company specialized in Artificial Intelligence for new drug design, and The Drug Discovery Unit (DDU), School of Life Sciences, The University of Dundee, focused on the discovery of therapeutics for neglected diseases and the translation of novel biology through small molecule drug discovery, announced entering a collaboration to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of DDU’s drug discovery programs. Under the agreement, Iktos will...

Read More

Business Insights

HALOZYME COMPLETES ANTARES PHARMA ACQUISITION

Halozyme Therapeutics, Inc. | May 30, 2022

news image

Halozyme Therapeutics, Inc. announced the successful completion of its acquisition of Antares Pharma, Inc. The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May 23, 2022. The minimum tender condition and all of the other conditions to the offer have been satisfied and on May 24, 2022, Halozyme accepted for payment and will promptly pay for all shares validly tendered and not vali...

Read More

HOW EHR-INTEGRATED PDMPS INCREASE INTEROPERABILITY, DECREASE BURDEN

EHRIntelligence | March 11, 2020

news image

A prescription drug monitoring program (PDMP) that is implemented into the EHR can decrease the strenuous process of checking the PDMP, thus reducing the cognitive workload and burden for the clinician. However, only one-in-three hospitals can access PDMP data within its EHR system. PDMPs are state-run electronic databases that have been deployed in 49 states, excluding Missouri. The program collects data from pharmacies on Drug Enforcement Agency (DEA) controlled substances and prescription dru...

Read More
news image

ALEXION BETS $1.4B ON PORTOLA AND ITS LAGGARD BLEEDING DRUG ANDEXXA

Fiercepharma | May 05, 2020

Alexion has made no secret of its plan to diversify beyond its blockbuster rare disease franchise. Now, the company has taken a flier out on a disappointing drug that targets severe bleeding—and it's hoping to parlay its hospital contacts into a sales boost that'll appease unruly investors. Alexion agreed to buy Portola Pharmaceuticals and its sole approved medicine, anticoagulant reversal agent Andexxa, in a deal valued at around $1.4 billion, the drugmakers said Monday. That'...

Read More
news image

Business Insights

IKTOS AND THE UNIVERSITY OF DUNDEE, DRUG DISCOVERY UNIT (DDU) ANNOUNCE A COLLABORATION TO USE AI FOR DRUG DESIGN AND RETROSYNTHEIS

Iktos | December 20, 2021

Iktos, a company specialized in Artificial Intelligence for new drug design, and The Drug Discovery Unit (DDU), School of Life Sciences, The University of Dundee, focused on the discovery of therapeutics for neglected diseases and the translation of novel biology through small molecule drug discovery, announced entering a collaboration to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of DDU’s drug discovery programs. Under the agreement, Iktos will...

Read More
news image

Business Insights

HALOZYME COMPLETES ANTARES PHARMA ACQUISITION

Halozyme Therapeutics, Inc. | May 30, 2022

Halozyme Therapeutics, Inc. announced the successful completion of its acquisition of Antares Pharma, Inc. The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May 23, 2022. The minimum tender condition and all of the other conditions to the offer have been satisfied and on May 24, 2022, Halozyme accepted for payment and will promptly pay for all shares validly tendered and not vali...

Read More
news image

HOW EHR-INTEGRATED PDMPS INCREASE INTEROPERABILITY, DECREASE BURDEN

EHRIntelligence | March 11, 2020

A prescription drug monitoring program (PDMP) that is implemented into the EHR can decrease the strenuous process of checking the PDMP, thus reducing the cognitive workload and burden for the clinician. However, only one-in-three hospitals can access PDMP data within its EHR system. PDMPs are state-run electronic databases that have been deployed in 49 states, excluding Missouri. The program collects data from pharmacies on Drug Enforcement Agency (DEA) controlled substances and prescription dru...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us